Rezulin (troglitazone) is now approved for INITIAL therapy of type 2 diabetes

September 1997

    Rezulin (troglitazone) is now approved for INITIAL therapy of type 2 diabetes...and for combo use with a sulfonylurea.

    Initially, it was approved only as add-on therapy for patients poorly controlled on insulin.

    For initial therapy, Rezulin works about as well as metformin (Glucophage) or a sulfonylurea. It lowers blood sugar about 50 mg/dL...and reduces glycosylated hemoglobin (HbA1c) up to 1.5%.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote